Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase 1 clinical study evaluating B...
Nova Biomedical announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Bio...
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to...
First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targe...
BriaCell is advancing a new generation of cancer immunotherapies designed to improve outcomes for patients with metastatic breast cancer and other solid tu...
SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing...
Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows New heat-stable and hyperactive proteins across the fibroblast growth...
Partnership pairs Applied StemCell's induced pluripotent stem cell technology with RoosterBio's engineered media, reagents, and scalable bioprocess syste...
The University of California, Irvine (UC Irvine) School of Medicine and GlyTR Therapeutics have developed a next‑generation AAV‑mediated CAR T‑cell...
Advancement of commercial-ready formulation supports scalability and late-stage development Aspen Neuroscience, Inc., a clinical-stage regenerative medi...
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, announced that the California Institute for Regenerative Medicine (C...
As biopharmaceutical innovation continues to evolve, analytical science is playing a more strategic role in accelerating development and supporting regulat...
Non-dilutive funding will support the commercialization, development, and expansion strategy for Sonire's Ultrasound-Guided HIFU Platform Sonire Therape...
Jetstream Venture Fund (Jetstream), an innovative interval fund dedicated to opening access to institutional-grade deal flow for a wider mainstream audienc...
© 2026 Biopharma Boardroom. All Rights Reserved.
